UNSPSC 51162410: Dextromethorphan/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.

UNSPSC 51162410 Dextromethorphan/phenylephrine is a Commodity code that, based on recent state and local solicitations, captures pharmaceutical products including naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and OTC products supplied to public health, county health, and state/local government facilities. The actual procurement activity under this code spans emergency medical supplies, community health initiatives, and institutional pharmaceutical distribution rather than the single active-ingredient formulation the code name suggests. Issuing bodies include county health departments and multi-state cooperative purchasing alliances coordinating on behalf of multiple participating jurisdictions and state government agencies, reflecting a mix of direct county procurement and cooperative purchasing vehicles that aggregate demand across state and local entities.

Recent activity centers on Florida and Minnesota with broader multi-state reach. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026 through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026 and resulting agreements effective July 1, 2026. Both solicitations require compliance with federal regulations, E-Verify, drug supply chain security, and current Good Manufacturing Practices, with products sourced through authorized pharmaceutical wholesalers.